We have demonstrated a downregulation of HPGD expression in TAM-resistant breast cancer both in vitro in multiple series of TAMs and TAMr isogenic cell line pairs and in clinical samples using retrospective immunohistochemistry studies and in silico approaches. The gene discussed is HPGD; the disease is breast carcinoma.